As a class, cyclooxygenase inhibitory NSAIDs may be
associated with renal and gastrointestinal toxicity. Sensitivity to
drug-associated adverse events varies with the individual patient.
Patients at greatest risk for renal toxicity are those that are
dehydrated, on concomitant diuretic therapy, or those with existing
renal, cardiovascular, and/or hepatic dysfunction. Concurrent
administration of potentially nephrotoxic drugs should be carefully
approached. NSAIDs may inhibit the prostaglandins that maintain normal
homeostatic function. Such antiprostaglandin effects may result in
clinically significant disease in patients with underlying or
pre-existing disease that has not been previously diagnosed. Since many
NSAIDs possess the potential to produce gastrointestinal ulcerations,
concomitant use with other anti-inflammatory drugs, such as NSAIDs or
corticosteroids, should be avoided or closely monitored. The concomitant
use of protein bound drugs with PREVICOX Chewable Tablets has not been
studied in dogs. Commonly used protein-bound drugs include cardiac,
anticonvulsant, and behavioral medications. The influence of concomitant
drugs that may inhibit the metabolism of PREVICOX Chewable Tablets has
not been evaluated. Drug compatibility should be monitored in patients
requiring adjunctive therapy.
The safe use of PREVICOX Chewable Tablets in pregnant,
lactating or breeding dogs has not been evaluated.
Adverse Reactions: Include vomiting, diarrhea, decreased appetite or anorexia, lethargy, pain, somnolence and hyperactivity.Not for use in
humans. Keep this and all medications out of the reach of children.
Federal law restricts
this drug to use by or on the order of a licensed veterinarian
Store at room temperature between 59-86 F (15-30 C)
Brief periods up to 104 F are permitted.
How Supplied: PREVICOX is
available as round, beige to tan, half-scored tablets in two strengths,
containing 57 mg or 227 mg firocoxib. Each tablet strength is supplied
in 10 count and 30 count blister packages and 60 count bottles.